Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data

[1]  J. Yang.  Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases , 2016 .

[2]  Martin McKee,et al.  Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.

[3]  S. Yusuf,et al.  Association of urinary sodium and potassium excretion with blood pressure. , 2014, The New England journal of medicine.

[4]  S. Yusuf,et al.  Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies , 2014, PloS one.

[5]  S. Yusuf,et al.  Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. , 2013, American heart journal.

[6]  W. Brouwer,et al.  easuring the affordability of medicines : Importance nd challenges , 2013 .

[7]  W. Brouwer,et al.  Practical measurement of affordability: an application to medicines. , 2012, Bulletin of the World Health Organization.

[8]  Mike Rayner,et al.  Incidence and 30-day case fatality for acute myocardial infarction in England in 2010: national-linked database study , 2012, European journal of public health.

[9]  John Spertus,et al.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.

[10]  S. Yusuf,et al.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.

[11]  H. Leufkens,et al.  Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. , 2011, Bulletin of the World Health Organization.

[12]  B. Norrving,et al.  Global atlas on cardiovascular disease prevention and control. , 2011 .

[13]  Martin McKee,et al.  Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries , 2010, PloS one.

[14]  M. V. van Mourik,et al.  Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data , 2010, BMC cardiovascular disorders.

[15]  Salim Yusuf,et al.  The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. , 2009, American heart journal.

[16]  D Ross-Degnan,et al.  Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis , 2009, The Lancet.

[17]  Section GE-iMTA.  Practical measurement of affordability: an application to medicines , 2009 .

[18]  D. Ross-Degnan,et al.  Medicines coverage and community-based health insurance in low-income countries , 2008, Health research policy and systems.

[19]  K. Fukino,et al.  The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. , 2007, Bulletin of the World Health Organization.

[20]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[21]  C. Murray,et al.  Household catastrophic health expenditure: a multicountry analysis , 2003, The Lancet.